Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Mar 2, 2026-- Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua ® through the country’s National Health Insurance coverage. Optune Lua is …